Douglas P. Baker Sells 3,768 Shares of OptimizeRx Co. (NASDAQ:OPRX) Stock

OptimizeRx Co. (NASDAQ:OPRX) CFO Douglas P. Baker sold 3,768 shares of the stock in a transaction dated Tuesday, September 14th. The stock was sold at an average price of $65.57, for a total value of $247,067.76. Following the sale, the chief financial officer now directly owns 44,796 shares in the company, valued at approximately $2,937,273.72. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Douglas P. Baker also recently made the following trade(s):

  • On Wednesday, September 8th, Douglas P. Baker sold 10,000 shares of OptimizeRx stock. The stock was sold at an average price of $67.25, for a total value of $672,500.00.
  • On Tuesday, August 24th, Douglas P. Baker sold 4,000 shares of OptimizeRx stock. The stock was sold at an average price of $61.50, for a total value of $246,000.00.
  • On Monday, June 28th, Douglas P. Baker sold 3,421 shares of OptimizeRx stock. The shares were sold at an average price of $63.00, for a total value of $215,523.00.

Shares of NASDAQ OPRX opened at $69.51 on Friday. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of 579.25 and a beta of 0.66. OptimizeRx Co. has a 1-year low of $17.01 and a 1-year high of $73.88. The stock’s 50-day moving average is $60.73 and its 200 day moving average is $54.27.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Wednesday, August 4th. The company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.08. The company had revenue of $13.63 million for the quarter, compared to analysts’ expectations of $12.35 million. OptimizeRx had a return on equity of 2.26% and a net margin of 3.98%. As a group, sell-side analysts anticipate that OptimizeRx Co. will post 0.3 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of OptimizeRx by 2.3% during the 2nd quarter. BlackRock Inc. now owns 1,104,157 shares of the company’s stock valued at $68,347,000 after buying an additional 25,268 shares in the last quarter. Vanguard Group Inc. grew its position in OptimizeRx by 12.5% during the 2nd quarter. Vanguard Group Inc. now owns 774,349 shares of the company’s stock worth $47,932,000 after acquiring an additional 86,181 shares during the last quarter. Artisan Partners Limited Partnership bought a new position in OptimizeRx during the 1st quarter worth approximately $37,653,000. Blair William & Co. IL grew its position in OptimizeRx by 0.4% during the 2nd quarter. Blair William & Co. IL now owns 755,074 shares of the company’s stock worth $46,739,000 after acquiring an additional 2,971 shares during the last quarter. Finally, First Light Asset Management LLC grew its position in OptimizeRx by 11.9% during the 2nd quarter. First Light Asset Management LLC now owns 664,842 shares of the company’s stock worth $41,154,000 after acquiring an additional 70,643 shares during the last quarter. 67.39% of the stock is currently owned by institutional investors.

Several analysts have weighed in on the company. B. Riley raised their price target on OptimizeRx from $80.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 5th. Zacks Investment Research cut OptimizeRx from a “buy” rating to a “hold” rating in a report on Thursday, July 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $70.80.

About OptimizeRx

OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support.

Read More: Liquidity

Insider Buying and Selling by Quarter for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.